Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes

Journal of Medicinal Chemistry

Volumn 59, Issue 5, 2016, Pages 1967-1983

  El Maatougui, Abdelaziz ^a,b   Azuaje, Jhonny ^a,b   González Gómez, Manuel ^a,b   Miguez, Gabriel ^a,b   Crespo, Abel ^a,b   Carbajales, Carlos ^a,b   Escalante, Luz ^a,b   García Mera, Xerardo ^b   Gutiérrez De Terán, Hugo ^c   Sotelo, Eddy ^a,b  

^a Universidade de Santiago de Compostela ^*  (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BENZIMIDAZOLE DERIVATIVE; CYCLIC AMP; IMIDAZOLE DERIVATIVE; LIGAND; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; PYRIMIDINONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; PROCESS OPTIMIZATION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; METABOLISM; SYNTHESIS;

ADENOSINE A2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINONES; RECEPTOR, ADENOSINE A2B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960881597     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01586     Document Type: Article

References (51)

1. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 364-374 10.1007/s002100000313
2. Murphree, L. J.; Linden, J. Adenosine receptors Encyclopaedia of Biol. Chem. 2004, 1, 34-39 10.1016/B0-12-443710-9/00007-7
3. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Linden, J.; Muller, C. E. Nomenclature and classification of adenosine receptors-An update Pharmacol. Rev. 2011, 63, 1-34 10.1124/pr.110.003285
4. Moro, S.; Deflorian, F.; Bacilieri, M.; Spalluto, G. Ligand-based homology modelling as attractive tool to inspect GPCR structural plasticity Curr. Pharm. Des. 2006, 12, 2175-2185 10.2174/138161206777585265
5. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in chinese hamster ovary cells Biochem. Pharmacol. 2001, 61, 443-448 10.1016/S0006-2952(00)00570-0
6. Adenosine Receptors in Health and Disease; Wilson, C. N.; Mustafa, S. J., Eds.; Handbook of Experimental Pharmacology, Vol. 193; Springer: Berlin, 2009.
7. Baraldi, P. G.; Tabrizi, M. A.; Gessi, S.; Borea, P. A. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility Chem. Rev. 2008, 108, 238-263 10.1021/cr0682195
8. Jacobson, K. A.; Gao, Z. G. Adenosine receptors as therapeutic targets Nat. Rev. Drug Discovery 2006, 5, 247-264 10.1038/nrd1983
9. Müller, C. E.; Jacobson, A. J. Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim. Biophys. Acta, Biomembr. 2011, 1808, 1290-1308 10.1016/j.bbamem.2010.12.017
10. 2B receptor from human brain Biochem. Biophys. Res. Commun. 1992, 187, 86-93 10.1016/S0006-291X(05)81462-7
11. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 2001, 53, 527-552
12. 2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE2029-F20 Mol. Pharmacol. 2005, 67, 2137-2147 10.1124/mol.104.009225
13. 2B receptors Pharmacol. Rev. 1997, 49, 381-402
14. 2A receptors in the central nervous system CNS Neurol. Disord.: Drug Targets 2012, 11, 664-674 10.2174/187152712803581100
15. 2B adenosine receptor signaling Biochim. Biophys. Acta, Biomembr. 2011, 1808, 1329-1339 10.1016/j.bbamem.2010.05.016
16. Müller, C. E.; Jacobson, A. J. Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim. Biophys. Acta, Biomembr. 2011, 1808, 1290-1308 10.1016/j.bbamem.2010.12.017
17. 2B adenosine receptor antagonists as clinical candidates Purinergic Signalling 2009, 5, 21-29 10.1007/s11302-008-9119-x
18. 2B receptor J. Med. Chem. 2001, 44, 170-179 10.1021/jm990499b
19. 2B adenosine receptor stimulation Invest. Ophthalmol. Visual Sci. 2001, 42, 2068-2073
20. Spicuzza, L.; Di Maria, G.; Polosa, R. Adenosine in the airways: Implications and applications Eur. J. Pharmacol. 2006, 533, 77-88 10.1016/j.ejphar.2005.12.056
21. 2B adenosine receptors Drug Dev. Res. 1999, 47, 45-53 10.1002/(SICI)1098-2299(199905)47:1<45::AID-DDR6>3.0.CO;2-U
22. Robeva, A. S.; Woodard, R.; Jin, X.; Gao, Z.; Bhattacharya, S.; Taylor, H. E.; Rosin, D. L.; Linden, J. Molecular characterization of recombinant human adenosine receptors Drug Dev. Res. 1996, 39, 243-252 10.1002/(SICI)1098-2299(199611/12)39:3/4<243::AID-DDR3>3.0.CO;2-R
23. 2B selective adenosine receptor antagonists J. Med. Chem. 2002, 45, 1500-1510 10.1021/jm011049y
24. Kim, Y. C.; Ji, X.; Melman, N.; Linden, J.; Jacobson, K. A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors J. Med. Chem. 2000, 43, 1165-1172 10.1021/jm990421v
25. 2B adenosine receptor antagonists J. Med. Chem. 2004, 47, 1434-1447 10.1021/jm0309654
26. 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines Bioorg. Med. Chem. Lett. 2008, 18, 1397-1401 10.1016/j.bmcl.2008.01.008
27. 2B adenosine receptor antagonists for treating diseases like asthma and diarrhea. WO 2003042214, 2003.
28. 2B adenosine receptor J. Med. Chem. 2006, 49, 282-299 10.1021/jm0506221
29. 2B adenosine receptor Bioorg. Med. Chem. 2008, 16, 2852-2869 10.1016/j.bmc.2008.01.002
30. 2B receptors Biochem. Pharmacol. 2004, 68, 305-312 10.1016/j.bcp.2004.03.026
31. 2B adenosine receptor subtypes: A molecular modeling investigation J. Med. Chem. 2003, 46, 4287-4296 10.1021/jm030852k
32. 2B adenosine receptor antagonists J. Med. Chem. 2012, 55, 1490-1499 10.1021/jm201177b
33. 2B adenosine receptor antagonist J. Med. Chem. 2007, 50, 2732-2736 10.1021/jm061333v
34. 2B adenosine receptor antagonist ACS Med. Chem. Lett. 2011, 2, 213-218 10.1021/ml100249e
35. 2B adenosine receptor antagonists ACS Med. Chem. Lett. 2013, 4, 1031-1036 10.1021/ml400185v
36. Multicomponent Reactions; Zhu, J.; Bienayme, H., Eds.; Wiley-VCH: Weinheim, Germany, 2005.
37. Morales, A.; Ochoa, E.; Suárez, M.; Verdecia, Y.; González, L.; Martín, N.; Quinteiro, M.; Seoane, C.; Soto, J. L. Novel hexahydrofuro[3,4-b]-2(1H)-pyridones from 4-aryl substituted 5-alkoxycarbonyl-6-methyl-3,4-dihydropyridones J. Heterocycl. Chem. 1996, 33, 103-107 10.1002/jhet.5570330118
38. Lebed, P. S.; Kos, P. O.; Polovinko, V. V.; Tolmachev, A. A.; Vovk, M. V. Synthesis of new polyfunctional 5,6,7,8-tetrahydroimidazo-[1,5-c]pyrimidin-5-ones by the Aza-Wittig reaction followed by intramolecular cyclization and 1,3-prototropic shift Russ. J. Org. Chem. 2009, 45, 921-927 10.1134/S1070428009060207
39. Pérez, R.; Beryozkina, T.; Zbruyev, O. I.; Haas, W.; Kappe, C. O. Traceless solid-phase synthesis of bicyclic dihydropyrimidones using multidirectional cyclization cleavage J. Comb. Chem. 2002, 4, 501-510 10.1021/cc0200181
40. Heravi, M. M.; Saeedi, M.; Beheshtiha, Y. S.; Oskooie, H. A. One pot chemoselective synthesis of novel fused pyrimidine derivatives Chem. Heterocycl. Compd. 2011, 47, 737-744 10.1007/s10593-011-0828-7
41. Ryabukhin, S. V.; Plaskon, A. S.; Boron, S. Y.; Volochnyuk, D. M.; Tolmachev, A. A. Aminoheterocycles as synthons for combinatorial biginelli reactions Mol. Diversity 2011, 15, 189-195 10.1007/s11030-010-9253-6
42. 3 adenosine antagonists J. Med. Chem. 2011, 54, 457-471 10.1021/jm100843z
43. Gutiérrez-de-Terán, H.; Keranen, H.; Azuaje, J.; Åqvist, J.; Sotelo, E. In G-Protein Coupled Receptor Screening Assays; Walker, J. M., Ed.; Methods in Molecular Biology, Vol. 1272; Springer: Clifton, NJ, 2015; pp 271-291.
44. 2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217 10.1126/science.1164772
45. Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, C. B.; Heitman, L. H.; Ijzerman, A. P.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric regulation of GPCRs by sodium ions Science 2012, 337, 232-236 10.1126/science.1219218
46. Schwartz, T. W.; Frimurer, T. M.; Holst, B.; Rosenkilde, M. M.; Elling, C. E. Molecular mechanism of 7TM receptor activation a global toggle switch model Annu. Rev. Pharmacol. Toxicol. 2006, 46, 481-519 10.1146/annurev.pharmtox.46.120604.141218
47. 2A antagonists using structure based drug design J. Med. Chem. 2012, 55, 1898-1903 10.1021/jm201376w
48. 2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293 10.1016/j.str.2011.06.014
49. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 1993, 234, 779-815 10.1006/jmbi.1993.1626
50. Maestro, version 9.8; Schrödinger, LLC: New York, NY, 2009.
51. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins: Struct., Funct., Genet. 2003, 52, 609-623 10.1002/prot.10465